UK begins trial of latest virus vaccine this week with 300 candidates

The British government said 300 healthy people will be immunized with two doses of the Covid-19 vaccine candidate developed at Imperial, which has been backed by 41 million pounds

testing, private laboratories, labs, vaccines, doctors, nurses, health, coronavirus
Oxford University recently began an advanced study involving 10,000 volunteers, and the US is preparing for even larger studies in July that involve 30,000 people.
AP | PTI London
3 min read Last Updated : Jun 16 2020 | 7:59 AM IST
Scientists at Imperial College London will start immunising people in Britain this week with their experimental coronavirus shot, becoming the latest entry into the race to find an effective vaccine to stop the pandemic.

In a statement on Monday, the British government said 300 healthy people will be immunized with two doses of the Covid-19 vaccine candidate developed at Imperial, which has been backed by 41 million pounds ($51 million) in government funding.

So far, the vaccine candidate developed by Imperial College London has only been tested in animals and in the laboratory, where it produced much higher levels of antibodies than would normally be seen in infected people.

Many scientists have warned that the pandemic might only be stopped with an effective vaccine, which typically takes years to develop.

In the long term, a viable vaccine could be vital for protecting the most vulnerable, enabling restrictions to be eased and helping people get back to normal life, said Robin Shattock, who is leading the vaccine research.

The vaccine uses synthetic strands of genetic code based on the virus. Once injected into the muscle, the body's own cells are instructed to make copies of a spiky protein on the coronavirus. That should in turn trigger an immune response so that the body can fight off any future Covid-19 infection.

About a dozen vaccine candidates are currently in early stages of testing in thousands of people. There are no guarantees any will work but there's increasing hope that at least some could be ready by the end of the year.

Oxford University recently began an advanced study involving 10,000 volunteers, and the US is preparing for even larger studies in July that involve 30,000 people each testing different candidates, including Oxford's and one made by the National Institutes of Health and Moderna Inc.

Scientists have never created vaccines from scratch this fast and it's far from clear that any will ultimately prove safe and effective. Still, numerous countries, including Britain, France, Germany, the Netherlands and the US, have already placed advance orders for millions of vaccines that could be available by the end of the year if they prove to be effective.

The World Health Organization noted on Monday that there have been about 100,000 new cases reported every day for the past two weeks and that relaxed restrictions in many countries have led to a new surge of cases.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusLockdownCoronavirus VaccineUS FDAVaccine

Next Story